Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L0NI
|
||||
| Former ID |
DNC013066
|
||||
| Drug Name |
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H34N6O8S2
|
||||
| Canonical SMILES |
CC1=CC(=CC(=C1CCC(=O)NC2CSSCC(NC(=O)C(NC(=O)CNC2=O)CC3=<br />CC=C(C=C3)[N+](=O)[O-])C(=O)N)C)O
|
||||
| InChI |
1S/C28H34N6O8S2/c1-15-9-19(35)10-16(2)20(15)7-8-24(36)32-23-14-44-43-13-22(26(29)38)33-28(40)21(31-25(37)12-30-27(23)39)11-17-3-5-18(6-4-17)34(41)42/h3-6,9-10,21-23,35H,7-8,11-14H2,1-2H3,(H2,29,38)(H,30,39)(H,31,37)(H,32,36)(H,33,40)/t21-,22-,23-/m0/s1
|
||||
| InChIKey |
UHOUPDXHBXXBLE-VABKMULXSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [1] | |
| Delta-type opioid receptor | Target Info | Inhibitor | [1] | ||
| Mu-type opioid receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Enkephalin release | |||||
| Opioid proenkephalin pathway | |||||
| Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP69:TCR Signaling Pathway | |||||
| Opioid Signalling | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.